-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
PharmaCielo Signs Sales Agreement With Brazilian Phyto-Therapeutic Company
PharmaCielo Signs Sales Agreement With Brazilian Phyto-Therapeutic Company
PharmaCielo Ltd. (OTCQX:PCLOF) (TSXV:PCLO) , the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., entered into a supply agreement with one of the largest phyto-therapeutic companies in the Brazilian market. The customer has an extensive distribution network across Latin America, and is also a certified B-Corp, reflecting its commitment to a transparent business model that measures social and environmental impacts.
PharmaCielo will be registered with Anvisa as the sole supplier to the customer for this product, and under the agreement, PharmaCielo will ship significant quarterly volumes of a proprietary CBD derivative formulation to the Customer, which will be utilized in the production of novel herbal medicines to be distributed across Latin America. The company expects to begin shipping during Q1 2023.
Management Changes
PharmaCielo has appointed Ian D. Atacan to its board of directors. Atacan has been the company's CFO since June 7, 2021.
PharmaCielo has appointed Dr. Decio Rabelo de Castro Filho as chief medical officer of the company, to advance the company's visibility within physician communities and with pharmaceutical organizations in Latin America, Europe and other key markets globally.
Dr. de Castro Filho is a medical doctor with over 20 years of experience in occupational medicine and marketing. During the course of his career, Dr. de Castro Filho has also acted as an expert medical witness for several large Brazilian companies. Dr. de Castro Filho is a graduate of the medical program at Pontifical Catholic University of Campinas and has a master's degree in Marketing from Escola Superior de Propaganda e Marketing ESPM in São Paulo. He holds a degree in cannabinoid medicine from the Wecann Academia school.
Photo: Benzinga; Sources: geralt, lindsayfox via Pixabay
Related News
PharmaCielo Ships CBD Full Spectrum Oil To A Brazilian Pharmaceutical Compan
PharmaCielo Q1 Revenue Increases 77.92% YoY, Discusses International Market
PharmaCielo Enters Spanish Market With Initial Shipment Of 300Kg Of CBD Full Spectrum Oil To Extractions Solutions
PharmaCielo Ltd. (OTCQX:PCLOF) (TSXV:PCLO) , the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., entered into a supply agreement with one of the largest phyto-therapeutic companies in the Brazilian market. The customer has an extensive distribution network across Latin America, and is also a certified B-Corp, reflecting its commitment to a transparent business model that measures social and environmental impacts.
PharmaCielo Ltd.(OTCQX：PCLOF)(多伦多证券交易所股票代码：PCLO)，哥伦比亚干花和药用级大麻提取物的主要种植者和生产商的加拿大母公司，PharmaCielo哥伦比亚控股公司, 签订了A供货协议与世界上最大的巴西市场上的植物治疗公司。该客户在拉丁美洲拥有广泛的分销网络，也是经过认证的B-Corp，反映了其对衡量社会和环境影响的透明商业模式的承诺。
PharmaCielo will be registered with Anvisa as the sole supplier to the customer for this product, and under the agreement, PharmaCielo will ship significant quarterly volumes of a proprietary CBD derivative formulation to the Customer, which will be utilized in the production of novel herbal medicines to be distributed across Latin America. The company expects to begin shipping during Q1 2023.
PharmaCielo将在Anvisa注册为该产品客户的唯一供应商，根据协议，PharmaCielo将每季度向客户发运大量专有CBD衍生配方，这些配方将用于生产将在拉丁美洲分销的新型草药。该公司预计将于2023年第一季度开始发货。
Management Changes
管理层变动
PharmaCielo has appointed Ian D. Atacan to its board of directors. Atacan has been the company's CFO since June 7, 2021.
PharmaCielo已任命伊恩·D·阿塔坎提交给其董事会。阿塔坎自2021年6月7日以来一直担任该公司的首席财务官。
PharmaCielo has appointed Dr. Decio Rabelo de Castro Filho as chief medical officer of the company, to advance the company's visibility within physician communities and with pharmaceutical organizations in Latin America, Europe and other key markets globally.
PharmaCielo已任命Decio Rabelo de Castro Filho博士AS首席医疗官为了提高公司在医生群体中的知名度，以及在拉丁美洲、欧洲和全球其他关键市场的制药组织中的知名度。
Dr. de Castro Filho is a medical doctor with over 20 years of experience in occupational medicine and marketing. During the course of his career, Dr. de Castro Filho has also acted as an expert medical witness for several large Brazilian companies. Dr. de Castro Filho is a graduate of the medical program at Pontifical Catholic University of Campinas and has a master's degree in Marketing from Escola Superior de Propaganda e Marketing ESPM in São Paulo. He holds a degree in cannabinoid medicine from the Wecann Academia school.
德·卡斯特罗·菲略博士是一名医生，在职业医学和市场营销方面拥有20多年的经验。在他的职业生涯中，德·卡斯特罗·菲略博士还曾为几家巴西大公司担任过专家医学证人。德·卡斯特罗·菲略博士毕业于坎皮纳斯天主教教皇大学的医学课程，并拥有圣保罗Escola Superior de Promotion e Marketing ESPM的市场营销硕士学位。他拥有韦肯学院大麻类药物的学位。
Photo: Benzinga; Sources: geralt, lindsayfox via Pixabay
图片来源：Geralt，lindsayfox
Related News
相关新闻
PharmaCielo Ships CBD Full Spectrum Oil To A Brazilian Pharmaceutical Compan
PharmaCielo向一家巴西制药公司运送CBD全光谱油
PharmaCielo Q1 Revenue Increases 77.92% YoY, Discusses International Market
PharmaCielo第一季度营收同比增长77.92%，探讨国际市场
PharmaCielo Enters Spanish Market With Initial Shipment Of 300Kg Of CBD Full Spectrum Oil To Extractions Solutions
PharmaCielo以首批300公斤CBD全光谱油进入西班牙市场
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧